JNJ vs SKYE

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...

Skye Bioscience remains a highly speculative, high-risk/high-reward opportunity with potential for 10x growth, contingent on overcoming severe financial challenges. The company validated its novel cannabinoid-derived therapeutic approach with positive top-line Phase 2a data for SBI-100 (glaucoma) in November 2024, demonstrating significant clinical de-risking and a substantial TAM. However, this c...